This virtual stakeholder meeting has the objective to bring together relevant UK stakeholders and discuss key topics related to access to ATMPs. ARM is coordinating similar interactions in other European countries.
Join this virtual event with ARM and CGT Catapult bringing together relevant UK stakeholders and discuss key topics related to access to ATMPs. ARM is coordinating similar interactions in other European countries.
Agenda
13.00 -14.00 Introductory session: Advanced therapy industrial and access policies in the UK and internationally
- Janet Lynch Lambert - CEO, ARM
- Lord Bethell - Parliamentary Under Secretary of State for Innovation
- Matthew Durdy – CEO, Cell and Gene Therapy Catapult
14.00 - 14.15 Break
14.15 - 15.15 Panel 1 HTA methods, RWE generation and use
Chair: Darren Walsh - Country Manager UK, Orchard Therapeutics
Panellists:
- Noreen Downes – Principal Pharmacist, SMC
- Josie Godfrey – Project Director, Duchenne UK, Project Hercules
- Prof. Ron Akehurst – Professor University of Sheeld
- Victoria Barrett – Head of HTA and Market Access, ABPI
- Panos Kefalas – Head of Health Economics and Market Access, Cell and Gene Therapy Catapult
15.30 - 16.30 Panel 2 Innovative payment schemes, current experience and new models
Chair: Graham Cookson - CEO, Office Health Economics
Panelists:
- Tamir Singer – Head of Commercial Development, NHS England
- Carla Deakin – Programme Director, Commercial & Managed Access, NICE
- Paul Catchpole – Value and Access Director, Association of the British Pharmaceutical Industry (ABPI)
- David Hawkins – Founder and CEO, Remedium Capital
- Chris Vann – COO, Autolus